Table 1.
Patients’ description
| Case 1 (PSP01) | Case 2 (PSP02) | Case 3 (PSP06) | Case 4 (PSP08) | Case 5 (PSP09) | |
|---|---|---|---|---|---|
| Demographic data and cell dose | |||||
| Gender | M | F | F | F | F |
| Age (years) | 60 | 66 | 65 | 65 | 68 |
| Disease duration (years) | 8 | 7 | 4 | 6 | 5 |
| Cell dose (×106/kg) | 1.4 | 1.7 | 2 | 1.8 | 1.2 |
| MMSE | |||||
| Baseline | 27.49 | 28.27 | 25.49 | 24.27 | 25.53 |
| 1-month | 27.49 | 25.27 | 26.49 | 24.27 | 28.53 |
| 12-month | 26.49 | 25.03 | na | 21.27 | na |
| H&Y | |||||
| Baseline | 4/5 | 4/5 | 4/5 | 4/5 | 4/5 |
| 1-month | 4/5 | 4/5 | 4/5 | 4/5 | 4/5 |
| 3-month | 4/5 | 4/5 | 4/5 | 4/5 | 4/5 |
| 6-month | 4/5 | 4/5 | na | 4/5 | na |
| 12-month | 4/5 | 4/5 | na | 4/5 | na |
| UPDRS III | |||||
| Baseline | 47 | 38 | 47 | 31 | 42 |
| 1-month | 45 (−4 %) | 37 (−3 %) | 36 (−23 %) | 31 (0 %) | 48 (+14 %) |
| 3-month | 47 (0 %) | 49 (+29 %) | 48 (+2 %) | 39 (+26 %) | 48 (+14 %) |
| 6-month | 45 (−4 %) | 51 (+34 %) | na | 40 (+29 %) | na |
| 12-month | 47 (0 %) | 47 (+24 %) | na | 40 (+29 %) | na |
| PSP-RS | |||||
| Baseline | 37 | 53 | 52 | 36 | 57 |
| 1-month | 41 (+11 %) | 40 (−25 %) | 46 (−12 %) | 39 (+8 %) | n.a. |
| 3-month | 44 (+19 %) | 39 (−26 %) | 43 (−17 %) | 46 (+28 %) | 51 (−11 %) |
| 6-month | 47 (+27 %) | 63 (+19 %) | na | 52 (+44 %) | na |
| 12-month | 47 (+27 %) | 57 (+8 %) | na | 53 (+47 %) | na |
Demographical data, cell dose, baseline and follow-up neuropsycological assessments by mini-mental state evaluation (MMSE) and clinical scoring using three different scales
For UPDRS and PSP-RS the values are reports as absolute value and percentage of variation from baseline (in brackets)
H&Y Hoehn-Yahr stage, UPDRS III Unified Parkinson’s Disease Rating Scale part III, PSP-RS PSP rating score, na not available